NuCana plc (NCNA) News
Follow NuCana plc (NCNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
NuCana plc (NCNA) Wins EU Composition Patent for NUC-7738
NuCana secured a European composition-of-matter patent (EP 3683225) for NUC-7738, adding to 85+ issued patents worldwide. NUC-7738 is in Phase 2 of a Phase 1/2 study, including a combo with Keytruda in PD-1 inhibitor—res
NEWS | Sep 30, 2026, 12:09 PM UTC
L
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
NUC-7738 is protected by over 85 issued patents worldwideEDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NuCana plc NASDAQ:NCNA (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”)
NEWS | Sep 30, 2026, 12:09 PM UTC
L
NuCana (NCNA) reports Q2 2026 financial results and business update
NuCana (NCNA) reports its second quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC